ITGB5 and cancer: However, the increased expression of GADD45B, ITGB5, MMP1, and BNDF was correlated with a decreased chemotherapy resistance of cancer cells to mithramycin, tramrtinib, ARRY-162, dabrafenib, selumetinib, vemurafenib, nilotinib, coimetinib, cyclophosphamide, oxaliplatin, and tamoxifen (Supplementary Fig. 4B).